Phase 3 CLL17 Trial Shows Equivalent 3-Year PFS Across Treatment Arms in Chronic Lymphocytic Leukemia
核心洞察
The CLL17 (搜索) trial reported equivalent 3-year progression-free survival across its treatment arms, according to a report from CancerNetwork.
Long-term questions remain unresolved despite the comparable 3-year PFS outcomes observed between the study arms in CLL17 (搜索).
The findings were highlighted alongside other hematology and oncology topics, including venetoclax plus azacitidine in AML and the small cell lung cancer (搜索) paradigm.
The CLL17 (搜索) trial reported equivalent 3-year progression-free survival (PFS) across its treatment arms, according to a report from CancerNetwork. Despite the comparable 3-year PFS results, long-term questions about the trial's findings remain open.
The CLL17 (搜索) data were presented in the context of broader hematology and oncology discussion, including a separate question of whether venetoclax plus azacitidine makes chemotherapy obsolete in AML. Coverage also flagged a WCLC 2026 session on how the small cell lung cancer (搜索) paradigm may change.